BCBA/GILD (BCBA/GILD)

Buenos Aires Stock Exchange: BCBA/GILD · ARS

ARS 65,675

-851.54 (-1.3%)· Recorded snapshot

Market cap	303.4T
Revenue (ttm)	45.1T
Net income (ttm)	-4.8T
EPS (ttm)	-ARS 1,006
P/E (forward)	18.7x
Dividend	ARS 742 (1.13%)
Volume	55

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 45.1T
Net income (ttm): -4.8T
EPS (ttm): -ARS 1,006
P/E (forward): 18.7x
Market cap: 303.4T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E18.7

P25 15P50 18.3P75 23.8

Trailing P/En/a

P25 25.1P50 32.2P75 41.5

ROE-20.7

P25 5P50 10.6P75 23.5

ROIC34.4

P25 7.2P50 13.5P75 19.8

Benchmarks · 1M

All BCBA/GILD indicators

Market & fundamental data

Available fields

225

Groups with data

Currency

USD

Showing 225 of 225 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	United States
Country code	AR
Earnings date	2026-10-29
Employees	17,000
Employees change	-600
Employees growth	-3.41%
Enterprise value	ARS 336.1T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1987
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	ARBCOM4601C4
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Market cap	ARS 303.4T
Next earnings date	2026-10-29
Price	ARS 65,675.00
Price currency	ARS
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-27
Symbol	bcba/GILD
Website	https://www.gilead.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	75.16x
Average P/E ratio (3Y)	133.64x
Average P/E ratio (5Y)	84.97x
Earnings yield	-1.53%
EV/EBIT	18.46x
EV/EBITDA	14.8x
EV/FCF	17.53x
EV/Sales	7.18x
FCF / EV yield	5.7%
FCF yield	6.32%
Forward P/E	18.73x
P/(FCF - SBC) ratio	17.02x
P/(OCF - SBC) ratio	16.2x
P/B ratio	17.44x
P/FCF ratio	15.82x
P/OCF ratio	15.11x
P/S ratio	6.72x
Price/EBITDA ratio	14.03x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	38.88%
EBITDA margin	47.94%
FCF margin	40.93%
Gross margin	79.6%
Operating margin	38.88%
Pretax margin	-6.42%
Profit margin	-10.64%
Profit per employee	ARS -282.4M
Profitable years	19
Revenue per employee	ARS 2.7B
ROA	14.09%
ROA (5Y)	10.85%
ROCE	30.88%
ROE	-20.68%
ROE (5Y)	24.33%
ROIC	34.37%
ROIC (5Y)	21.93%
SBC / revenue	2.98%
Tax / revenue	4.22%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
FCF growth	38.15%
FCF growth (Q)	376.81%
FCF growth (QoQ)	41.45%
FCF growth 3Y	13.19%
FCF growth 5Y	8.85%
Gross profit growth	6.96%
Gross profit growth (Q)	11.52%
Gross profit growth 3Y	3.69%
Gross profit growth 5Y	1.75%
Net income growth years	1
OCF growth	37.33%
OCF growth (Q)	332.04%
OCF growth (QoQ)	40.45%
OCF growth 10Y	-2.84%
OCF growth 3Y	12.52%
OCF growth 5Y	8.31%
Operating income growth	7.34%
Operating income growth (Q)	-5.23%
Operating income growth 3Y	6.62%
Operating income growth 5Y	-1.1%
Revenue growth	5.52%
Revenue growth (Q)	10.18%
Revenue growth (QoQ)	12.11%
Revenue growth 10Y	-0.61%
Revenue growth 3Y	3.61%
Revenue growth 5Y	2.72%
Revenue growth quarters	5
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -902.2B
Depreciation and amortization	ARS 4.2T
EBIT	ARS 17.5T
EBITDA	ARS 21.6T
EPS	ARS -1,005.63
Financing cash flow	ARS -6.9T
Free cash flow	ARS 19.2T
Free cash flow minus SBC	ARS 17.8T
Gross profit	ARS 35.9T
Income taxes	ARS 1.9T
Investing cash flow	ARS -16.1T
Net borrowing	ARS 2T
Net cash flow	ARS -2.9T
Net income	ARS -4.8T
Operating cash flow minus SBC	ARS 18.7T
Operating income	ARS 17.5T
Revenue	ARS 45.1T
Stock-based compensation	ARS 1.3T

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.05
Book value per share	ARS 14,121.40
Debt / EBITDA	1.78
Debt / equity	2.23
Debt / FCF	2.03
Goodwill	ARS 12.8T
Interest coverage	11.86
Long-term assets	ARS 51.7T
Long-term liabilities	ARS 38.8T
Net cash (debt)	ARS -31.7T
Net cash / market cap	-10.43%
Net debt / EBITDA	1.46
Net debt / equity	1.82
Net debt / FCF	1.65
Piotroski F-Score	5
Property, plant and equipment	ARS 9T
Shareholders' equity	ARS 17.4T
Tangible book value	ARS -15.6T
Tangible book value per share	ARS -12,555.15
Total assets	ARS 73.1T
Total cash	ARS 7.2T
Total debt	ARS 38.9T
Total liabilities	ARS 55.7T

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.58
Current assets	ARS 21.5T
Current liabilities	ARS 17T
Current ratio	1.27
Inventory turnover	3.29
Net working capital	ARS 677B
Quick ratio	0.9
Working capital	ARS 4.3T
Working capital turnover	13,982.66

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.39%
Dividend growth	26.7%
Dividend growth (3Y)	86.47%
Dividend growth (5Y)	79.64%
Dividend growth years	6
Dividend payment date	2026-09-29
Dividend payment years	8
Dividend payout frequency	Quarterly
Dividend per share	ARS 742.18
Dividend yield	1.13%
Ex-dividend date	2026-09-15
Last dividend	ARS 195.89
Shareholder yield	2.52%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	ARS 53,570.63
1D price change	-1.28%
1M price change	8.02%
1M total return	8.02%
1W price change	5.76%
1W total return	5.76%
1Y price change	38.85%
1Y return CAGR	41.21%
1Y total return	41.18%
20-day SMA	ARS 61,655.00
200-day SMA	ARS 53,244.30
3M price change	27.15%
3M total return	27.83%
3Y price change	282.31%
3Y return CAGR	59.18%
3Y total return	303.48%
50-day SMA	ARS 60,160.50
50-day SMA vs 200-day SMA	50over200
52-week high	ARS 66,675.00
52-week high date	2026-10-26
52-week low	ARS 41,540.00
52-week low date	2025-10-27
5Y price change	1,821.16%
5Y return CAGR	83.54%
5Y total return	1,982.2%
6M price change	34.69%
6M total return	35.94%
All-time high	ARS 66,675.00
All-time high date	2026-10-26
All-time low	ARS 656.50
All-time low date	2019-04-22
Average true range (ATR)	ARS 1,485.10
Average volume	546.3
Change from 52-week high	-1.5%
Change from 52-week low	58.1%
Change from all-time high	-1.5%
Change from all-time low	9,903.81%
Change from open	0.27%
Day's gap	-1.54%
Dollar volume	ARS 3.6M
High price	ARS 65,750.00
Low price	ARS 65,175.00
Monthly RSI	82.22
Open price	ARS 65,500.00
Position in 52-week range	86.96%
Previous close	ARS 66,525.00
Price vs 150-day SMA	22.6%
Price vs 20-day SMA	6.52%
Price vs 200-day SMA	23.35%
Price vs 50-day SMA	9.17%
Relative volume	0.1
RSI	65.49
Sharpe ratio	1.4
Sharpe ratio (3Y)	1.36
Sharpe ratio (5Y)	1.67
Sortino ratio	2.32
Sortino ratio (3Y)	2.2
Sortino ratio (5Y)	2.73
Volume	55
Weekly RSI	71.52
YTD price change	40.15%
YTD total return	41.94%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.2B
Shares change (QoQ)	-0.88%
Shares change (YoY)	-1.39%
Shares held by insiders	0.09%
Shares held by institutions	90.91%
Short ratio	3.3 days

Deeper analysis on BCBA/GILD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/GILD report

Is a complete BCBA/GILD research report available?

No complete published report is available for bcba/GILD (BCBA/GILD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/GILD (BCBA/GILD)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/GILD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/GILD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/GILD

Frequently asked questions